Riliprubart Demonstrates Maintained Efficacy, Safety in Subgroup Analyses of CIDP
Nusinersen-Related Improvements in Motor Function Correlate With Reduced Autophagy Markers of Spinal Muscular Atrophy
Sarcopenia Shows Association to Higher Risk of Chemotherapy-Induced Peripheral Neurotoxicity
Biomarker and Subgroup Insights on Novel CIDP Therapy Riliprubart: Luis Querol, MD, PhD